GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (STU:GHDN) » Definitions » E10

Brainstorm Cell Therapeutics (STU:GHDN) E10 : €-0.68 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Brainstorm Cell Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Brainstorm Cell Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was €-0.046. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.68 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was -5.50% per year. During the past 5 years, the average E10 Growth Rate was -11.50% per year. During the past 10 years, the average E10 Growth Rate was 8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Brainstorm Cell Therapeutics was 32.40% per year. The lowest was -20.10% per year. And the median was 9.40% per year.

As of today (2024-06-06), Brainstorm Cell Therapeutics's current stock price is €0.392. Brainstorm Cell Therapeutics's E10 for the quarter that ended in Mar. 2024 was €-0.68. Brainstorm Cell Therapeutics's Shiller PE Ratio of today is .


Brainstorm Cell Therapeutics E10 Historical Data

The historical data trend for Brainstorm Cell Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brainstorm Cell Therapeutics E10 Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.49 -0.51 -0.61 -0.63 -0.61

Brainstorm Cell Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.51 -0.67 -0.69 -0.61 -0.68

Competitive Comparison of Brainstorm Cell Therapeutics's E10

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brainstorm Cell Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's Shiller PE Ratio falls into.



Brainstorm Cell Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Brainstorm Cell Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.046/131.7762*131.7762
=-0.046

Current CPI (Mar. 2024) = 131.7762.

Brainstorm Cell Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201406 -0.118 100.560 -0.155
201409 -0.124 100.428 -0.163
201412 -0.146 99.070 -0.194
201503 -0.111 99.621 -0.147
201506 -0.107 100.684 -0.140
201509 -0.125 100.392 -0.164
201512 -0.064 99.792 -0.085
201603 -0.090 100.470 -0.118
201606 -0.045 101.688 -0.058
201609 -0.080 101.861 -0.103
201612 -0.038 101.863 -0.049
201703 -0.093 102.862 -0.119
201706 -0.053 103.349 -0.068
201709 -0.109 104.136 -0.138
201712 0.017 104.011 0.022
201803 -0.097 105.290 -0.121
201806 -0.137 106.317 -0.170
201809 -0.129 106.507 -0.160
201812 -0.237 105.998 -0.295
201903 -0.212 107.251 -0.260
201906 -0.204 108.070 -0.249
201909 -0.227 108.329 -0.276
201912 -0.306 108.420 -0.372
202003 -0.290 108.902 -0.351
202006 -0.222 108.767 -0.269
202009 -0.119 109.815 -0.143
202012 -0.304 109.897 -0.365
202103 -0.160 111.754 -0.189
202106 -0.141 114.631 -0.162
202109 -0.128 115.734 -0.146
202112 -0.150 117.630 -0.168
202203 -0.136 121.301 -0.148
202206 -0.180 125.017 -0.190
202209 -0.192 125.227 -0.202
202212 -0.123 125.222 -0.129
202303 -0.131 127.348 -0.136
202306 -0.120 128.729 -0.123
202309 -0.028 129.860 -0.028
202312 -0.101 129.419 -0.103
202403 -0.046 131.776 -0.046

Add all the adjusted EPS together and divide 10 will get our e10.


Brainstorm Cell Therapeutics  (STU:GHDN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Brainstorm Cell Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Brainstorm Cell Therapeutics (STU:GHDN) Business Description

Traded in Other Exchanges
Address
1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Brainstorm Cell Therapeutics (STU:GHDN) Headlines

No Headlines